NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental ...

Sanofi, Regeneron eye $11B in Dupixent sales with ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain about 400,000 shares in Regeneron stock ...

Sanofi and Regeneron rejiggered their longstanding antibody ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain around 400,000 shares in ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

U.S. drugmaker Regeneron Pharmaceuticals said on Monday it would repurchase about $5 billion of its shares directly from France's Sanofi, without altering their over-a-decade-long partnership.

Sanofi recognizes all revenue from antibodies in the partnership. The drug accounted for €10.7 billion (about $11.6 billion) in sales in 2023, up nearly 30% from the prior year, according to the ...

Regeneron struck a deal to pay Sanofi $900 million, plus another $200 million in milestones, to secure full global rights to the asset. By Frank Vinluan on June 02, 2022 Share ...

Tucked away in the middle of its second-quarter results today, Regeneron announced that it and long-term Big Pharma partner Sanofi will end their antibody research partnership before 2018.

But Sanofi has begun to talk up its internal efforts and step back from key partnerships, most notably with Regeneron. Cancer immuno-oncology multiple myeloma partnerships EuroBiotech Report ...

Both Sanofi and Regeneron are expected to benefit from expected approvals for key drugs in March and April. The approvals themselves may be priced in, but sales to a lesser extent.

French drugmaker Sanofi SA <SASY.PA> is buying more shares in U.S. biotech company Regeneron Pharmaceuticals Inc <REGN.O>, its partner in the development of potential blockbuster treatments for ...